Previous models of cytotherapies with MSCs in MM included placenta-derived MSCs [19] that showed a native activity against MM cells in vitro in parallel with a moderate osteogenic potential in vivo in healing the MM bone lesions in SCID-rab mice. The gene discussed is AGFG1; the disease is Miyoshi myopathy.